Transnational Research Imaging Core (TRI)

再生医学和组织工程是创新的治疗方法，在 解决未得到满足的临床需求。这些新产品和新技术在人类医学中的应用 受限于临床前安全性和有效性测试的复杂性。与拥有主要NIH的州相比 资金，对从事翻译工作的学术科学家、工程师和行业专家来说是一个重大障碍 南卡罗来纳州的再生医学努力缺乏资源来维持和发展现有的 通过跟上成本高昂的新技术创新、合规性问题的快速步伐，实现核心设施 以及推进新发现所需的监管协议。这阻碍了初步数据的生成 NIH有竞争力的提案，限制了我们追求应用再生医学努力以造福 南卡罗来纳州的人口。 推进在第一阶段和第二阶段确立的组织工程和再生医学目标 通过我们的Cobre中心(SC BioCRAFT)，我们建议升级和进一步开发我们原来的细胞、组织和 分子分析核心向更面向翻译的核心转化，名为翻译研究成像(TRI) 核心。这个第三阶段的核心已经被设想为先进的生物分析推力的组合 显微镜和成像以及用于小动物和大动物试验的临床前验证推力。 三核中心的总体使命是支持学术科学家、工程师和生物医学行业专家。 在追求新的生物材料和技术的临床前验证方面，并增强其潜力 竞争性的外部资金。为了实现这一使命，我们提出了两个具体目标：1)提供切割- 干细胞生物学、外植体分析、体内细胞跟踪、高级组织学、光和 电子成像和3D图像重建能力以及2)提供最先进的设施和 通过为小动物和大动物提供再生医学方法的临床前验证的专业知识 手术和长期测试和成像能力，包括数字放射成像、临床CT和MRI。 由经验丰富的美国国立卫生研究院资助的科学家指导的杰出设施和实验室将提供 为所有试点项目PI以及对开发感兴趣的科学家和工程师提供指导环境 再生医学项目。第三阶段之后的核心活动和可持续性的管理将 由我们的校园核心管理软件促进，通过建立用户费用和使用 代金券计划。拟议的三核，连同互补的生物材料工程和 测试核心都得到了克莱姆森大学的大力支持，将极大地增强研究能力和 推进在南卡罗来纳州内创建再生医学强国的潜力。

Regenerative medicine and tissue engineering are innovative therapeutic approaches that hold great promise in addressing unmet clinical needs. Application of these novel products and technologies in human medicine is limited by the complexities of pre-clinical safety and efficacy testing. By comparison to states with major NIH funding, a significant obstacle for academic scientists, engineers and industry experts involved with translational regenerative medicine efforts in the State of South Carolina is the lack of resources to sustain and evolve existing core facilities by keeping up with the rapid pace of new and costly technological innovations, compliance issues and regulatory protocols needed to advance new discoveries. This hinders the generation of preliminary data for competitive NIH proposals and limits our ability to pursue applied regenerative medicine efforts to benefit the population of South Carolina. To advance the goals of tissue engineering and regenerative medicine that were established in Phases I and II by our COBRE Center (SC BioCRAFT) we propose to upgrade and further develop our original Cell, Tissue and Molecular Analysis core into a more translationally oriented core entitled Translational Research Imaging (TRI) core. This Phase III core has been envisioned as the combination of a bio-analytical thrust for advanced microscopy and imaging and a pre-clinical validation thrust for small and large animal testing. The overall mission of the TRI core is to support academic scientists, engineers and biomedical industry experts in their pursuit of pre-clinical validation of novel biomaterials and technologies and enhance their potential for competitive extramural funding. To achieve this mission, we propose two specific aims: 1) to provide cutting- edge capabilities for stem cell biology, explant analysis, in vivo cell tracking, advanced histology, light and electron imaging and 3D image reconstruction capabilities and 2) to provide state-of-the-art facilities and expertise for pre-clinical validation of regenerative medicine approaches by offering small and large animal surgery and long-term testing and imaging capabilities including digital radiography, clinical CT and MRI. Outstanding facilities and labs directed by experienced NIH-funded scientists will provide a collaborative mentoring environment to all pilot projects PIs and to scientists and engineers interested in developing regenerative medicine projects. Management of core activities and sustainability beyond the Phase III period will be facilitated by our campus-wide core management software, by establishment of user fees and by using a voucher program. The proposed TRI core, together with the complementary Biomaterials Engineering and Testing core, both very strongly supported by Clemson University, will greatly enhance research capabilities and advance the potential for creation of a regenerative medicine powerhouse within the state of South Carolina.